Relationship between Tetracyclines’ Structure and Minimal Inhibitory Concentration of Streptococcus spp.

M. Marczak; T. Grabowski; M. Feder

doi:10.1055/s-0034-1387718

Drug Research, Table of Contents

Drug Res (Stuttg) 2015; 65(08): 410-415
DOI: 10.1055/s-0034-1387718

Original Article

Relationship between Tetracyclines’ Structure and Minimal Inhibitory Concentration of Streptococcus spp.

M. Marczak

¹Dofarm, Aksamitna, Błonie, Poland

,

T. Grabowski

²Polpharma Biologics, Gdańsk, Poland

,

M. Feder

³Department of Research and Development, Adamed Sp. z o.o., Czosnów, Poland

› Author Affiliations

Abstract

During the past years, a growing number of bacterial strains have become resistant to tetracyclines. The problem of increasing resistance and lack of susceptibility to tetracyclines applies to strains isolated from both: animals and humans. Basic tools to design new drugs and determining the direction of the search for new molecules is the analysis of the relationship between the chemical structure and the pharmacokinetic and pharmacodynamic parameters. Purpose of this study is to determine the relationship between physicochemical parameters of tetracyclines and MIC₅₀ and MIC₉₀ values determined for Streptococcus spp. Analysis of physicochemical parameters of selected drugs was made using MarvinSketch 5.11.5 (ChemAxon Ltd.) and QuickProp 3.1 software from Schrödinger package v 31207. MIC₅₀ and MIC₉₀ values were correlated with 51 calculated physicochemical parameters and arithmetic expressions. Internal and external model validation was performed using leave-one out method. 4 arithmetic expressions fulfilled all validation criteria, but only in relation to MIC₅₀. A new method to optimize the tetracyclines’ structure in relation to Streptococcus spp. was presented. It was also shown that the relations of structure: antimicrobial activity type can have different nature depending on MIC₅₀ or MIC₉₀ of specific bacterial strain.

Key words

in silico - MIC - tetracycline - validation - structure

Full Text

References

References
1 Markiewicz Z, Kwiatkowski ZA. Bakterie, antybiotyki, lekooporność. In: Mostowik K. (ed.) Warszawa: Wydawnictwo Naukowe PWN; 2011. 9,66,133
2 The European Union Summary Report on antimicrobial resistance in zoonotic and identicator bacteria from humans, animals and food in 2011. EFSA J 2013; 11: 3196
3 EC Commission Decision of 12 June 2007 on a harmonised monitoring of antimicrobial resistance in Salmonella in poultry and pigs. Official Journal of the European Union 2007; L 153/261: 1-4
4 Brandon M, Dowzicky MJ. Antimicrobial susceptibility among Gram-positive organisms collected from pediatric patients globally between 2004 and 2011: results from the Tigecycline Evaluation and Surveillance Trial. J Clin Microbiol 2013; 51: 2371-2378
5 Laurens C, Michon AL, Marchandin H et al. Clinical and antimicrobial susceptibility data of 140 Streptococcus pseudopneumoniae isolates in France. Antimicrob Agents Chemother 2012; 56: 4504-4507
6 Nomoto R, Tien le HT, Sekizaki T et al. Antimicrobial susceptibility of Streptococcus gallolyticus isolated from humans and animals. Jpn J Infect Dis 2013; 66: 334-336
7 ECDC Transatlantic Taskforce on Antimicrobial Resistance, Recommendations for future collaboration between the U.S. and EU. 2011; 1-42
8 Brodersen DE, Clemons WM, Carter AP et al. The structural basis for the action of the antibiotics tetracycline, pactamycin, and hygromycin b on the 30s ribosomal subunit. Cell 2000; 103: 1143-1154
9 Jenner L, Starosta AL, Terry DS et al. Structural basis for potent inhibitory activity of the antibiotic tigecycline during protein synthesis. Proc Natl Acad Sci 2013; 110: 3812-3816
10 Chopra I. Tetracycline analogs whose primary target is not the bacterial ribosome. J Antimicrob Agents Chemother 1994; 38: 637-40
11 Chopra I, Hawkey PM, Hinton M. Tetracyclines, molecular and clinical aspects. J Antimicrob Chemother 1992; 29: 245-77
12 Dax SL. Antibacterial chemotherapeutic agents. 1st ed. London, United Kingdom: Blackie Academic and Professional; 1997: 1-416
13 Mitscher LA. The chemistry of the tetracycline antibiotics. New York, N.Y: Marcel Dekker, Inc; 1978
14 Rogalski W. Chemical modification of the tetracyclines. In: Hlavka JJ, Boothe JH. (ed.) Handbook of experimental pharmacology. Vol. 78. Berlin: Springer-Verlag KG; 1985: 179-316
15 Zakeri B, Wright GD. Chemical biology of tetracycline antibiotics. Biochem Cell Biol 2008; 86: 124-136
16 The Antimicrobial Index, Knowledgebase, version 1.8. TOKU-E, 2013. antibiotics.toku-e.com
17 Ioakimidis L, Thoukydidis L, Mirza A et al. Benchmarking the Reliability of QikProp. Correlation between experimental and predicted values. QSAR Comb. Sci 2007; 27: 445-456
18 QuicProp 3.1 from Schrödinger v 31207. Available from Schrödinger, LLC 2007 http://www.schrodinger.com/products/14/17/
19 Grabowski T, Jaroszewski JJ, Gad SC et al. Correlation between in silico physicochemical characteristics of drugs and their mean residence time in human and dog. Int J Toxicol 2012; 31: 25-33
20 OECD The report from the expert group on (Quantitative) Structure-Activity Relationships [(Q)SARs] on the principles for the validation of (Q)SARs. 2004; 11-198
21 OECD Guidance document on the validation of (quantitative) structure-activity relationships [(Q)SAR] models, OECD. 2007; series on testing and assessment No. 69 1-154
22 Kubinyi H. QSAR: Hansch analysis and related approaches. Methods and principles. Weinheim: Vol. 1. Wiley-VCH; 1993: 20-190
23 Pratim RP, Paul S, Mitra I et al. On two novel parameters for validation of predictive QSAR models. Molecules 2009; 14: 1660-1701
24 Leardi R. Nature-inspired methods in chemometrics: genetic algorithms and artificial neural networks: genetic algorithms and artificial neural networks. 1st ed Elsevier Science; 2003
25 Tonn S, Rowland M. Quantitative structure pharmacokinetic activity relationships with some tetracyclines [proceedings]. J Pharm Pharmacol 1979; 31 (Suppl): 43)
26 Topliss J. Quantitative Structure-Activity Relationships of Drugs. London: 1st ed. Academic Press; 1983: 87
27 Liu Y, Ramamurthy N, Marecek J et al. The lipophilicity, pharmacokinetics, and cellular uptake of different chemically-modified tetracyclines (CMTs). Curr Med Chem 2001; 8: 243-252
28 Di Stefano A, Sozio P, Iannitelli A et al. Characterization of alkanoyl-10-O-minocyclines in micellar dispersions as potential agents for treatment of human neurodegenerative disorders. Eur J Pharm Sci 2008; 34: 118-128
29 Kuhn P, Eyer K, Allner S et al. A microfluidic vesicle screening platform: monitoring the lipid membrane permeability of tetracyclines. Anal Chem 2011; 23: 8877-85
30 Maffeis L, Veraldi S. Minocycline in the treatment of acne: latest findings. G Ital Dermatol Venereol 2010; 145: 425-429
31 Fuoco D. Classification framework and chemical biology of tetracycline-structure-based drugs. Antibiotics 2012; 1: 1-13